文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

系统评价和荟萃分析淋巴结微转移和 I 期-IIIA 期非小细胞肺癌患者孤立肿瘤细胞的预后影响。

Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer.

机构信息

Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.

Department of Biomedical Data Science, section Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Histopathology. 2023 Apr;82(5):650-663. doi: 10.1111/his.14831. Epub 2022 Nov 9.


DOI:10.1111/his.14831
PMID:36282087
Abstract

Lymph node micrometastases could be one of the reasons for the high recurrence rate after complete surgical resection in stage I-IIIA non-small cell lung cancer (NSCLC). The standard evaluation of a single haematoxylin and eosin (H&E) slide of a paraffin-embedded section of a lymph node is insufficient for the detection of micrometastases, and there is a need for additional histopathological evaluation. The association of lymph node micrometastases with survival remains as yet unresolved. The aim of this systematic review and meta-analysis is to investigate if lymph node micrometastases and isolated tumour cells in patients with stage I-IIIA NSCLC, detected with multiple sectioning and/or immunohistochemistry (IHC) and/or reverse transcriptase polymerase chain reaction (RT-PCR), are associated with overall survival (OS) and disease-free survival (DFS) after surgical resection. We performed a meta-analysis of time-to-event outcomes based on 15 articles using ancillary techniques to detect micrometastases. We extracted the OS and DFS every 3-6 months after surgery, for patients with and without occult lymph node micrometastasis, from the survival curves published in each article. These data were used to reconstruct OS and DFS for 'micrometastasis' and 'no micrometastasis' groups. Based on all included studies that used IHC, serial sectioning, or RT-PCR, we found a 5-year OS of 55% (micrometastasis) vs. 75% (no micrometastasis), and a 5-year DFS of 53% (micrometastasis) vs. 75% (no micrometastasis). Patients with stage I-IIIA NSCLC with lymph node micrometastases detected by ancillary histopathological and molecular techniques have a significantly poorer OS and DFS compared to patients without lymph node micrometastases.

摘要

淋巴结微转移可能是 I 期-IIIA 期非小细胞肺癌(NSCLC)患者完全手术后高复发率的原因之一。对石蜡包埋淋巴结切片的单个苏木精和伊红(H&E)染色的标准评估不足以检测微转移,需要额外的组织病理学评估。淋巴结微转移与生存的关系尚未解决。本系统评价和荟萃分析的目的是研究在 I 期-IIIA 期 NSCLC 患者中,使用多切片和/或免疫组织化学(IHC)和/或逆转录聚合酶链反应(RT-PCR)检测到的淋巴结微转移和孤立肿瘤细胞是否与手术后的总生存期(OS)和无病生存期(DFS)相关。我们使用辅助技术对 15 篇文章进行了时间事件结果的荟萃分析,以检测微转移。我们从发表的每篇文章的生存曲线中提取了手术后每 3-6 个月 OS 和 DFS,包括有和无隐匿性淋巴结微转移的患者。这些数据用于为“微转移”和“无微转移”组重建 OS 和 DFS。基于所有使用 IHC、连续切片或 RT-PCR 的纳入研究,我们发现 5 年 OS 为 55%(微转移)vs. 75%(无微转移),5 年 DFS 为 53%(微转移)vs. 75%(无微转移)。通过辅助组织病理学和分子技术检测到淋巴结微转移的 I 期-IIIA 期 NSCLC 患者的 OS 和 DFS 明显较差。

相似文献

[1]
Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer.

Histopathology. 2023-4

[2]
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.

Cochrane Database Syst Rev. 2025-5-27

[3]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[4]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[5]
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Cochrane Database Syst Rev. 2022-9-26

[6]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[7]
Surgery for early stage non-small cell lung cancer.

Cochrane Database Syst Rev. 2005-1-25

[8]
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Cochrane Database Syst Rev. 2021-5-4

[9]
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.

Cochrane Database Syst Rev. 2022-1-7

[10]
Electronic cigarettes for smoking cessation.

Cochrane Database Syst Rev. 2025-1-29

引用本文的文献

[1]
Feasibility of intraoperative indocyanine green injection to identify lymph nodes at risk of metastatic disease for early-stage lung cancer.

JTCVS Tech. 2025-5-21

[2]
Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study.

Ann Surg Oncol. 2025-7-10

[3]
Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions.

J Clin Med. 2025-6-11

[4]
Investigation of sentinel lymph nodes using SPECT/CT and perioperative gamma assay combined with immunohistochemistry in non-small cell lung cancer patients undergoing lung resection.

Indian J Thorac Cardiovasc Surg. 2025-7

[5]
Long-Term Oncologic Outcomes in Robot-Assisted and Video-Assisted Lobectomies for Non-Small Cell Lung Cancer.

J Clin Med. 2023-10-19

[6]
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward.

Onco Targets Ther. 2023-2-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索